UBS lowered the firm’s price target on Quest Diagnostics (DGX) to $175 from $176 and keeps a Neutral rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics introduces testing for Oropouche virus
- Quest Diagnostics: Strategic Positioning and Growth Potential Amid Reimbursement Challenges
- Quest Diagnostics to develop multi-cancer blood test with MD Anderson Center
- Quest Diagnostics management to meet with Oppenheimer
- Quest Diagnostics: Strong Growth Prospects and Strategic Initiatives Drive Buy Rating